A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare® In Combination With Tamsulosin in OAB Residual Symptoms

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00333112

Acronym

VICTOR

Enrollment

398

Registered

2006-06-02

Start date

2006-05-31

Completion date

2007-01-31

Last updated

2014-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Incontinence

Keywords

Treatment Outcome, Urology, Solifenacin succinate, Urinary Incontinence

Brief summary

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

Detailed description

A 2 arm study ( 1 Active, 1 Placebo) to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men

Interventions

DRUGsolifenacin succinate

Oral

DRUGtamsulosin

oral

DRUGplacebo

oral

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

* Symptoms of Overactive Bladder (OAB)

Exclusion criteria

* Current use of antimuscarinic therapy * Evidence of a urinary tract infection

Design outcomes

Primary

Measure	Time frame
Change in micturitions per 24 hours from baseline to end of treatment	18 weeks

Secondary

Measure	Time frame
Change in urgency episodes per 24 hours from baseline to end of treatment	18 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026